Pharmaceutical

Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease

The goal had been for 10,000 patients to be on Leqembi by the end of March 2024, but only 2,000 patients received the drug as of 26 January.

Feb 28, 2024 - 18:00
Biogen discontinues Aduhelm to focus on Leqembi for Alzheimer’s disease
The goal had been for 10,000 patients to be on Leqembi by the end of March 2024, but only 2,000 patients received the drug as of 26 January.
Read the original article

Tags:

Previous Article

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

Next Article

Beacon Therapeutics unveils promising interim results for gene therapy AGTC-501

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma

STAT+: FDA investigating whether CAR-T, a treatment for...

Nov 29, 2023

FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy 

FDA grants RMAT designation to Taysha’s Rett syndrome g...

May 5, 2024

CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma

CHMP backs MSD’s KEYTRUDA approval for urothelial carci...

Jul 30, 2024